London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year

blonca9
Nov 19, 2024
1 min read

CEO Sander van Deventer describes the science behind delivering antibodies this way, and learnings he has taken away from the gene therapy field. Plus, the investments in manufacturing the company has already been making.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight